A multidisciplinary approach for the treatment of GIST liver metastasis
© Radkani et al; licensee BioMed Central Ltd. 2008
Received: 23 October 2007
Accepted: 09 May 2008
Published: 09 May 2008
Advanced gastrointestinal stromal tumors (GISTs) can metastasize and recur after a long remission period, resulting in serious morbidity, mortality, and complex management issues.
A 67-year-old woman presented with epigastric fullness, mild jaundice and weight loss with a history of a bowel resection 7 years prior for a primary GIST of the small bowel. The finding of a heterogeneous mass 15.5 cm in diameter replacing most of the left lobe of the liver by ultrasonography and CT, followed by positive cytological studies revealed a metastatic GIST. Perioperative optimization of the patient's nutritional status along with biliary drainage, and portal vein embolization were performed. Imatinib was successful in reducing the tumor size and facilitating surgical resection.
A well-planned multidisciplinary approach should be part of the standard management of advanced or metastatic GIST.
Gastrointestinal stromal tumors (GISTs) are neoplasms of the gastrointestinal tract. Despite their less aggressive pathologic nature, GISTs can metastasize and recur after a long remission period. Such cases may produce serious morbidity, mortality, and complex management issues for the treating physician. We hereby report the case of a patient who presented with an isolated metastatic GIST to the liver that was successfully treated with a multidisciplinary approach including imatinib therapy, portal vein embolization, and hepatic lobectomy.
total billirubin: 4, direct billirubin: 3.93, alkaline phosphatase: 942, AST: 124, ALT: 156. The addition laboratory values were within normal limit.
The patient was admitted to the hospital for additional work-up. A percutaneous transhepatic cholangiogram was performed, with placement of a right biliary drainage catheter for decompression. The bilirubin and liver function tests at the day before drainage placement were as follow: total billirubin: 4 direct billirubin: 3.93 ALK: 942 AST: 124 ALT: 156. Two days later the labs were as follow: total billirubin: 3.45 direct billirubin: 3.28, alkaline phosphatase: 788 AST: 117 ALT: 123, and 30 days later was: total billirubin: 0.7 direct billirubin: 0.30 alkaline phosphatase: 130 AST: 28 ALT: 25. A core liver biopsy was also done at the time, which demonstrated atypical spindle cells. Immuno-histochemical studies yielded positive CD117, vimentin and actin stains, all consistent with GIST. It was later established that the patient had previously undergone a small bowel resection for a primary GIST. Upper and lower endoscopy as well as small bowel series were subsequently performed. These revealed no tumors of the GI tract, suggesting the liver mass was a late and isolated metastatic manifestation of the prior GIST tumor.
The patient then underwent portal vein embolization (PVE) in hopes of promoting hypertrophy of the right lobe and further atrophy of the tumor-laden left hepatic lobe, in preparation for surgical resection.
Gastrointestinal stromal tumors are the most common mesenchymal neoplasms of the GI tract. They have an overall incidence of 3000–5000 cases per year in the United States [1–3]. It is thought that these tumors differentiate from intestinal pacemaker cells, also known as interstitial cells of Cajal . They affect mostly males between the ages of 50 and 70, and are usually found incidentally at early stages [1–4]. Large or advanced lesions may present with a variety of clinical findings, including bleeding, abdominal pain, early satiety, bowel obstruction, or perforation.
GISTs are usually detected by endoscopy, CT or MRI performed for abdominal symptoms. The gold standard for diagnosing GISTs is pathological tissue examination, which normally demonstrates atypical splindle cells. A positive stain for CD117 carries a specificity of 95% for these tumors, and will unequivocally establish a diagnosis [1–7].
When GISTs originate in the small bowel, they behave in a more aggressive manner . The most common site for metastases is the liver and the peritoneal cavity, but can also occur in bone, skin, soft tissues, and lymph nodes . Negative prognostic factors for aggressiveness and recurrence include tumor size, a high mitotic index, or an unknown site of origin [9, 10]. Recurrence usually occurs 19–26 months after surgery [3, 11, 12]. For this reason, the National Comprehensive Cancer Network suggests routine follow-up CT scans of the abdomen and pelvis every 3–6 month for the first 3–5 years after resection .
The only definitive treatment for GISTs is surgical resection. This can be done laparoscopically in some cases, or with the traditional open approach. The mainstay of surgical therapy in primary or metastatic disease is to achieve a complete resection with negative margins . Conventional chemotherapy and radiation therapy may have minor adjunctive benefits in unresectable or metastatic GISTs . Imatinib mesylate (Gleevec®), a selective inhibitor of tyrosine kinase, has revolutionized the management of this disease in recent years. Imatinib has a significant shrinking effect on GISTs, and can be used when primary GISTs have attained a very large size or are in unfavorable locations, increasing the risk of positive resection margins . Imatinib has also become the first line of treatment for recurrent and/or metastatic GISTs, as described for the patient in this case report . Imatinib is generally very well tolerated; and most patients can tolerate treatment without interruption. The more common side effects of Imatinib mesylate include [14, 15]: nausea, vomiting, diarrhea, and muscle cramps. It is common to see a decrease in the neutrophil and platelet counts especially during the first month of therapy . The drug should be stopped to allow recovery if the absolute neutrophil count (ANC) falls to <1,000/microL and/or the platelet count to <50,000/microL during the first months of therapy . Our patient had no evidence of these side effects during therapy. More recently, sunitinib malate (Sutent®), a multikinase inhibitor has been approved by the Food and Drug Administration for treatment of GISTs that are refractory to imatinib .
Resection of GIST liver metastases may be curative when the primary disease has been eradicated and negative surgical resection margins are attained. However, a large tumor burden in the hepatic parenchyma may prohibit resection given the risk of insufficient remaining liver tissue and subsequent postoperative liver failure . An option to counteract this phenomenon is the use of portal vein embolization (PVE) in cases of unilobular involvement of the liver. First used in the 1980s, selective PVE induces atrophy of a selected liver region as well as a compensatory hypertrophy of the remaining liver parenchyma [20–23]. Preoperative PVE is recommended if less than 30% to 40% of normal the liver is expected to remain and be functional after resection [24, 25].
This case, to our best knowledge, represents the first in the literature describing a multidisciplinary approach for the successful management of a large metastasic GIST to the liver. We attribute the success of this case to a well thought out management plan set forth by a dedicated tumor board utilizing advanced and evidence-based therapeutic modalities. Timing and resource utilization were key factors in the management of this patient. Perioperative optimization of the patient's nutritional status and state of health with biliary drainage was helpful. The pharmacologic effect of imatinib reduced the tumor size and improved the surgical resectability. Additionally, PVE facilitated the operation and promoted healthy liver tissue hypertrophy. Lastly, careful operative technique and dedicated follow up allowed for a good surgical outcome in this patient. A well-planned multidisciplinary approach should be part of the standard management of advanced or metastatic GISTs.
Written consent of the patient was obtained for publication of this case report.
The authors would like to thank Antonio Martinez, MD, from the department of pathology at Mount Sinai Medical Center for his help and contribution in the pathology aspects of this manuscript.
- Gold JS, DeMatteo RP: Combined surgical and medical therapy, the gastrointestinal stromal tumor model. Ann Surg. 2006, 244: 176-184. 10.1097/01.sla.0000218080.94145.cf.PubMed CentralView ArticlePubMedGoogle Scholar
- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000, 231: 51-58. 10.1097/00000658-200001000-00008.PubMed CentralView ArticlePubMedGoogle Scholar
- Langer C, Gunawan B, Schüler P, Huber W, Füzesi L, Becker H: Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg. 2003, 90: 332-339. 10.1002/bjs.4046.View ArticlePubMedGoogle Scholar
- Miettinen M, El-Rifai W, HL Sobin L, Lasota J: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol. 2002, 33: 478-483. 10.1053/hupa.2002.124123.View ArticlePubMedGoogle Scholar
- Miettinen M, Lasota J: Gastrointestinal stromal tumors; review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006, 130: 1466-1478.PubMedGoogle Scholar
- Dematteo RP, Maki RG, Antonescu C, Brennan MF: Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg. 2003, 40: 144-193. 10.1067/msg.2003.022223.View ArticlePubMedGoogle Scholar
- Zwan Van Der SM, Dematteo RP: Gastrointestinal stromal tumors: 5 years later. Cancer. 2005, 104: 1781-1788. 10.1002/cncr.21419.View ArticlePubMedGoogle Scholar
- DeMatteo RP: The GIST of targeted cancer therapy: a tumor, a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002, 9: 831-839. 10.1007/BF02557518.View ArticlePubMedGoogle Scholar
- Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol. 1999, 23: 82-87. 10.1097/00000478-199901000-00009.View ArticlePubMedGoogle Scholar
- Berman J, O'Leary TJ: Gastrointestinal stromal tumor workshop. Hum Pathol. 2001, 32: 578-582. 10.1053/hupa.2001.25484.View ArticlePubMedGoogle Scholar
- Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow CJ: Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001, 8: 50-59. 10.1007/s10434-001-0050-4.View ArticlePubMedGoogle Scholar
- Pierie JP, Choudry U, Muzikansky A, Yeap BY, Souba WW, Ott MJ: The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001, 136: 383-389. 10.1001/archsurg.136.4.383.View ArticlePubMedGoogle Scholar
- Blackstein ME, Rankin C, Fletcher C, Heinrich M, Benjamin R, von Mehren M, Blanke C, Fletcher JA, Borden E, Demetri G: Clinical benefit of imatinib in patients with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. J Clin Oncol. 2005, 23 (16 suppl): 9010-http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=34&abstractID=34173Google Scholar
- Guilhot F: Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004, 9: 271-281. 10.1634/theoncologist.9-3-271.View ArticlePubMedGoogle Scholar
- Schiffer CA: BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007, 357: 258-265. 10.1056/NEJMct071828.View ArticlePubMedGoogle Scholar
- Deininger MW, O'Brien SG, Ford JM, Druker BJ: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003, 21: 4255-4256. 10.1200/JCO.2003.11.143.View ArticleGoogle Scholar
- Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J: Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. 2004, 100: 2592-2597. 10.1002/cncr.20285.View ArticlePubMedGoogle Scholar
- Maki RG: Recent advances in therapy for gastrointestinal stromal tumors. Curr Oncol Rep. 2007, 9: 165-169. 10.1007/s11912-007-0017-0.View ArticlePubMedGoogle Scholar
- Hao CY, Ji JF: Surgical treatment of colorectal cancer: strategies and controversies. Eur J Surg Oncol. 2006, 32: 473-483. 10.1016/j.ejso.2006.02.016.View ArticlePubMedGoogle Scholar
- Kokudo N, Makuuchi M: Current role of portal vein embolization and hepatic artery chemoembolization. Surg Clin North Am. 2004, 84: 643-657. 10.1016/j.suc.2003.12.004.View ArticlePubMedGoogle Scholar
- Jaeck D, Bachellier P, Nakano H, Oussoultzoglou E, Weber JC, Wolf P, Greget M: One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg. 2003, 185: 221-229. 10.1016/S0002-9610(02)01373-9.View ArticlePubMedGoogle Scholar
- Kawasaki S, Makuuchi M, Kakazu T, Miyagawa S, Takayama T, Kosuge T, Sugihara K, Moriya Y: Resection for multiple metastatic liver tumors after portal embolization. Surgery. 1994, 115: 674-677.PubMedGoogle Scholar
- de Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V: Preoperative portal vein embolization for extension of hepatectomy. Hepatology. 1996, 24: 1386-1391. 10.1002/hep.510240612.View ArticlePubMedGoogle Scholar
- Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T: Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997, 26: 1176-1181.PubMedGoogle Scholar
- Madoff DC, Abdalla EK, Vauthey JN: Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Intrv Radiol. 2005, 16: 770-790.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.